Home›Legal›TB-500 in Texas
TB-500 in Texas: Legal Status & Provider Guide (2026)
Quick Answer
TB-500 is a prescription substance in the United States. TB-500 / Thymosin Beta-4 is explicitly identified in FDA guidance as not suitable for 503A/503B compounding. Federal compliance risk for providers offering it is high. Patients should understand the legal status before use. In Texas, compounding is governed by the Texas State Board of Pharmacy (TSBP). In Texas, physician assistants and nurse practitioners with prescriptive authority can prescribe compounded medications including peptides. Prescribers must hold an active Texas license. Telemedicine prescribing of controlled substances and certain compounded medications is permitted under Texas Medical Board rules with specific conditions.
Federal Legal Status
FDA Approval Status
TB-500 is a synthetic peptide derived from thymosin beta-4. It is not FDA-approved and not on the FDA bulk substances lists for compounding. FDA has explicitly listed thymosin beta-4 in guidance indicating it cannot be compounded by 503A/503B facilities.
Compounding Pharmacy Rules (Federal)
TB-500 (thymosin beta-4) is specifically mentioned in FDA guidance as a substance that does not meet the criteria for 503A bulk compounding. It cannot be lawfully compounded by facilities subject to FDA oversight. Some providers offer it under research or investigational frameworks, but this carries significant federal compliance risk.
Also Known As
Thymosin Beta-4 · Tβ4
Primary Research Areas
- Tissue repair
- Wound healing
- Inflammation reduction
- Angiogenesis
Texas Pharmacy Board & Compounding Rules
Regulator
Compounding Overview
Texas is home to one of the largest compounding pharmacy industries in the country, with detailed rules set by the Texas State Board of Pharmacy (TSBP). Texas 503A pharmacies may compound non-FDA-approved peptides under certain conditions, though federal FDA guidance takes precedence for pharmacies participating in the national regulatory framework. Texas-specific rules address sterile compounding standards, USP 797 compliance, and registration requirements for non-resident pharmacies shipping into the state.
Notable Rules
- Texas TSBP requires sterile compounding facilities to comply with USP 797 standards.
- Non-resident (out-of-state) pharmacies shipping compounded products into Texas must be registered with the TSBP.
- Texas prohibits the sale of prescription-only compounded products without a valid prescription.
- The Texas Medical Board regulates prescribing standards for telemedicine encounters including peptide programs.
Prescribing Requirements in Texas
In Texas, physician assistants and nurse practitioners with prescriptive authority can prescribe compounded medications including peptides. Prescribers must hold an active Texas license. Telemedicine prescribing of controlled substances and certain compounded medications is permitted under Texas Medical Board rules with specific conditions.
About TB-500
TB-500 is the synthetic version of the naturally occurring thymosin beta-4, a protein ubiquitous in human and animal cells. Research has focused on its role in wound healing, angiogenesis, and tissue repair. Human clinical trial data is limited.
For more research information, mechanism of action, and provider availability, see the TB-500 research profile on PeptideBase.
Frequently Asked Questions
- Is TB-500 the same as thymosin beta-4?
- TB-500 is a synthetic peptide fragment derived from thymosin beta-4, specifically the actin-binding domain. The two are often used interchangeably in informal contexts, though they are not identical. FDA guidance on thymosin beta-4 applies to TB-500 in practice.
TB-500 Providers in Texas
No providers currently listed in Texas for TB-500. Browse the full directory to find providers offering TB-500.
Browse all TB-500 providers →TB-500 Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare TB-500 legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .